L Bodei1, G Pepe, G Paganelli. 1. Nuclear Medicine Divisions, European Instituteof Oncology, Milano, Italy.
Abstract
BACKGROUND: Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs. RESULTS AND CONCLUSIONS: Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.
BACKGROUND: Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs. RESULTS AND CONCLUSIONS: Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.
Authors: Matthaeus Cieciera; Clemens Kratochwil; Jan Moltz; Hans Ulrich Kauczor; Tim Holland Letz; Peter Choyke; Walter Mier; Uwe Haberkorn; Frederik L Giesel Journal: Diagn Interv Radiol Date: 2016 May-Jun Impact factor: 2.630
Authors: Richard P Baum; Andreas Kluge; Franz Josef Gildehaus; Marcus Bronzel; Karl Schmidt; Christiane Schuchardt; Stephan Senftleben; Samuel Samnick Journal: Nucl Med Mol Imaging Date: 2011-11-16
Authors: Aura D Herrera-Martínez; Manuel D Gahete; Sergio Pedraza-Arevalo; Rafael Sánchez-Sánchez; Rosa Ortega-Salas; Raquel Serrano-Blanch; Raúl M Luque; María A Gálvez-Moreno; Justo P Castaño Journal: Endocrine Date: 2017-12-01 Impact factor: 3.633